<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677898</url>
  </required_header>
  <id_info>
    <org_study_id>IIR 07-256</org_study_id>
    <nct_id>NCT00677898</nct_id>
  </id_info>
  <brief_title>A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs)</brief_title>
  <official_title>A Patient-Centered Approach to Improve Screening for Side Effects of SGAs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if individuals with serious mental illnesses
      exposed to a patient-centered computerized tool versus printed educational materials have
      higher rates of screening for the metabolic side effects of second-generation antipsychotic
      medications and different patterns of communication with their prescribers about screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Project Background/Rationale: Second-generation antipsychotic (SGA) medications are widely
      used to treat psychotic disorders but are associated with metabolic side effects such as
      weight gain, glucose dysregulation, and hyperlipidemia that may contribute to the high rates
      of cardiovascular disease observed in individuals with serious mental illness (SMI).
      Adherence to guidelines for regular screening for the metabolic side effects of SGAs is
      inadequate. Patient-centered care, characterized by an effective partnership between
      clinicians and patients that promotes active participation by patients in their own care,
      improves health outcomes and satisfaction in the general population. In order to increase
      rates of screening for the metabolic side effects of SGAs, we propose to design a
      patient-centered computerized tool that provides veterans with SMI with personalized health
      information on how well their care adheres to screening recommendations. The computerized
      tool will use principles shown to enhance usability in persons with cognitive impairments.

      Project Objectives: The objectives of this study are to determine the effect of exposure to a
      patient-centered computerized tool compared to enhanced treatment as usual (e-TAU) on: (1)
      rates of screening for and identification of health problems associated with the metabolic
      side effects of SGAs; (2) patterns of patient-centered communication around screening for
      metabolic side effects and VA patients' self-efficacy in communicating with their
      psychiatrists about screening; (3) VA patients' preferences for obtaining health information
      and participating in decision-making about screening; and (4) VA patients' perceptions of
      their psychiatrists' participatory decision-making styles around screening.

      Project Methods: A total of 240 veterans with psychotic disorders prescribed SGAs and in
      regular contact with their prescribing clinicians in outpatient mental health clinics in the
      VA Maryland Health Care System will be recruited for this randomized controlled trial. Half
      of participants will be randomly assigned to the intervention condition in which they will
      view a brief computer program that provides personalized health information on adherence to
      guidelines for screening of metabolic side effects that is designed to facilitate discussion
      with psychiatrists about appropriate screening. The other half of participants will receive
      enhanced treatment-as-usual (e-TAU) consisting of printed information on the metabolic side
      effects of SGAs and general recommendations for screening. Participants will be exposed to
      the intervention or e-TAU up to 3 times immediately prior to a visit with their prescriber
      over the one-year study period. Rates of screening for the metabolic side effects of SGAs
      will be obtained from patients' computerized medical records. A single prescriber visit for
      each participant will be audiotaped and coded with the Roter Interaction Analysis System
      (RIAS) to characterize patterns of patient-clinician communication around screening for
      metabolic side effects. Baseline and 12-month follow-up interview assessments with veterans
      will be used to acquire information on self-efficacy, their preferences for obtaining health
      information and participating in decisions regarding side effect screening, and important
      covariates such as severity of psychiatric illness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Body Mass Index</measure>
    <time_frame>1 year</time_frame>
    <description>Guidelines recommend that body mass index be evaluated every 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Blood Pressure</measure>
    <time_frame>1 year</time_frame>
    <description>Guidelines recommend that blood pressure be evaluated every 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Blood Glucose/HbA1c</measure>
    <time_frame>1 year</time_frame>
    <description>Guidelines recommend that blood glucose/HbA1c be evaluated every year</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: LDL Cholesterol</measure>
    <time_frame>1 year</time_frame>
    <description>Guidelines recommend that LDL cholesterol be evaluated every 2 years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: HDL Cholesterol</measure>
    <time_frame>1 year</time_frame>
    <description>Guidelines recommend that HDL cholesterol be evaluated every 2 years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Triglycerides</measure>
    <time_frame>1 year</time_frame>
    <description>Guidelines recommend that triglycerides be evaluated every 2 years</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>Patient-centered computerized tool</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Written educational materials</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Patient-centered computerized tool</intervention_name>
    <description>A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects</description>
    <arm_group_label>Patient-centered computerized tool</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Written educational materials</intervention_name>
    <description>Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening</description>
    <arm_group_label>Written educational materials</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agreement obtained from the treating clinician that the patient is clinically stable
             enough to participate in the study and can be contacted for recruitment

          -  Agreement obtained from treating clinician to have a single visit with the patient
             audio taped

          -  Patient age 18-70 years

          -  Diagnosis of a psychotic disorder (schizophrenia, affective psychosis, major
             depression with psychotic features)

          -  Currently prescribed any SGA medication (aripiprazole, clozapine, olanzapine,
             quetiapine, risperidone, ziprasidone) by a clinician in a VA Maryland Healthcare
             System (VAMHCS) mental health clinic

          -  Had at least two outpatient visits with the prescribing clinician in the past year -
             Decisional capacity to provide informed consent

          -  Ability to read at a 4th grade reading level

        Exclusion Criteria:

          -  Diagnosis of dementia or other organic brain syndrome or traumatic brain injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Anne Kreyenbuhl, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Park SG, Derman M, Dixon LB, Brown CH, Klingaman EA, Fang LJ, Medoff DR, Kreyenbuhl J. Factors associated with shared decision-making preferences among veterans with serious mental illness. Psychiatr Serv. 2014 Dec 1;65(12):1409-13. doi: 10.1176/appi.ps.201400131. Epub 2014 Nov 17.</citation>
    <PMID>25178383</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2008</study_first_posted>
  <results_first_submitted>September 5, 2014</results_first_submitted>
  <results_first_submitted_qc>September 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2014</results_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patient-Centered Care</keyword>
  <keyword>Adverse effects</keyword>
  <keyword>Antipsychotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patient-centered Computerized Tool</title>
          <description>A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects</description>
        </group>
        <group group_id="P2">
          <title>Written Educational Materials</title>
          <description>Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patient-centered Computerized Tool</title>
          <description>A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects</description>
        </group>
        <group group_id="B2">
          <title>Written Educational Materials</title>
          <description>Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="239"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" spread="8.0"/>
                    <measurement group_id="B2" value="53.5" spread="8.6"/>
                    <measurement group_id="B3" value="54.3" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Body Mass Index</title>
        <description>Guidelines recommend that body mass index be evaluated every 3 months</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patient-centered Computerized Tool</title>
            <description>A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects</description>
          </group>
          <group group_id="O2">
            <title>Written Educational Materials</title>
            <description>Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Body Mass Index</title>
          <description>Guidelines recommend that body mass index be evaluated every 3 months</description>
          <units>percentage of days in the study period</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" spread="22.5"/>
                    <measurement group_id="O2" value="76.1" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Blood Pressure</title>
        <description>Guidelines recommend that blood pressure be evaluated every 3 months</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patient-centered Computerized Tool</title>
            <description>A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects</description>
          </group>
          <group group_id="O2">
            <title>Written Educational Materials</title>
            <description>Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Blood Pressure</title>
          <description>Guidelines recommend that blood pressure be evaluated every 3 months</description>
          <units>percentage of days in the study period</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5" spread="21.8"/>
                    <measurement group_id="O2" value="78.5" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Blood Glucose/HbA1c</title>
        <description>Guidelines recommend that blood glucose/HbA1c be evaluated every year</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patient-centered Computerized Tool</title>
            <description>A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects</description>
          </group>
          <group group_id="O2">
            <title>Written Educational Materials</title>
            <description>Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Blood Glucose/HbA1c</title>
          <description>Guidelines recommend that blood glucose/HbA1c be evaluated every year</description>
          <units>percentage of days in the study period</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" spread="10.7"/>
                    <measurement group_id="O2" value="96.2" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: LDL Cholesterol</title>
        <description>Guidelines recommend that LDL cholesterol be evaluated every 2 years</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patient-centered Computerized Tool</title>
            <description>A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects</description>
          </group>
          <group group_id="O2">
            <title>Written Educational Materials</title>
            <description>Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: LDL Cholesterol</title>
          <description>Guidelines recommend that LDL cholesterol be evaluated every 2 years</description>
          <units>percentage of days in study period</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" spread="17.0"/>
                    <measurement group_id="O2" value="95.1" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: HDL Cholesterol</title>
        <description>Guidelines recommend that HDL cholesterol be evaluated every 2 years</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patient-centered Computerized Tool</title>
            <description>A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects</description>
          </group>
          <group group_id="O2">
            <title>Written Educational Materials</title>
            <description>Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: HDL Cholesterol</title>
          <description>Guidelines recommend that HDL cholesterol be evaluated every 2 years</description>
          <units>percentage of days in study period</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" spread="16.6"/>
                    <measurement group_id="O2" value="95.2" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Triglycerides</title>
        <description>Guidelines recommend that triglycerides be evaluated every 2 years</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patient-centered Computerized Tool</title>
            <description>A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects</description>
          </group>
          <group group_id="O2">
            <title>Written Educational Materials</title>
            <description>Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days in the Study Period That a Patient's Screening for Metabolic Side Effects of Second-generation Antipsychotic Medications Adheres to Guidelines: Triglycerides</title>
          <description>Guidelines recommend that triglycerides be evaluated every 2 years</description>
          <units>percentage of days in the study period</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" spread="16.6"/>
                    <measurement group_id="O2" value="94.5" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Patient-centered Computerized Tool</title>
          <description>A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects</description>
        </group>
        <group group_id="E2">
          <title>Written Educational Materials</title>
          <description>Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>All deaths that occurred during the study were reported to the local Institutional Review Board (IRB) and were determined to be unrelated to study participation.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric hospitalization</sub_title>
                <description>All psychiatric hospitalizations that occurred during the study were reported to the local Institutional Review Board (IRB) and were determined to be unrelated to study participation.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julie Kreyenbuhl, Pharm.D., Ph.D.</name_or_title>
      <organization>VA VISN 5 Mental Illness Research, Education and Clinical Center</organization>
      <phone>410-637-1864</phone>
      <email>Julie.Kreyenbuhl@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

